Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Army's $10B Software Contract Aims for Speed in Modernization Effort

Oct 24, 2024•over 1 year ago

Contract Type

contract

BiotechnologyHealth CareVenture Capital

Description

The United States Army is on track to create a huge new ID/IQ contract valued at $10 billion over 10 years to modernize the way it buys and builds software. Potential bidders have until the end of this week to offer comments on the Army's latest draft request for proposals, with 15-20 firms set to win spots on the contract. The accelerated timeline for the contract is unprecedented in the world of large federal ID/IQ contracts, with plans for one more draft RFP and an industry day before the final version of the solicitation that vendors will bid on.

Company Information

Company

Army

About

The Cardiff Advisory Managing Partner has decades of experience guiding life sciences and healthcare companies through significant growth, has won the Alzheimer's Association of San Diego 2023 Hope Award and has been named among San Diego's 500 Most Influential People for the past four years. Recognized as one. David H. Crean, Ph.D., is a seasoned leader with over three decades of extensive experience in mergers and acquisitions, strategic partnerships and investments in the dynamic sectors of life sciences and health care. His expertise spans a variety of roles across leading biopharmaceutical institutions, investment banking and the venture capital and private equity landscape. At the helm of Cardiff Advisory LLC as Managing Partner, Dr. Crean runs a boutique firm that specializes in M&A, strategic advisory services and investment banking, serving life sciences and business clients through significant growth and exit strategies. Focuses on guiding healthcare companies. Senna Biosciences, Inc. is a private biopharmaceutical company in La Jolla, California, entering the clinical phase. The company focuses on the discovery and development of innovative medicines for the prevention and treatment of Alzheimer's disease. Senna has a transformative, innovative and differentiated patented technology that targets the underlying cause of disease and addresses previous failures by others. IND filing of Senna's first-in-class peptide drug is planned within the next few months.

Predictive Intelligence
Strategic

ML-powered predictions for Army's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.